Procter & Gamble Health announces results for the Fourth Quarter & Fiscal Year ended March 31, 2026

Procter & Gamble Health Ltd. ("the Company") today announced its financial results for the fourth quarter and financial year ended March 31, 2026. During the quarter, the Company delivered sales of ₹365 crores, up 20% versus a year ago, driven by strong brand fundamentals and positive consumer response to new innovations. Profit After Tax (PAT) stood at ₹95 crores for the quarter, up 55% versus a year ago led by superior brand building activities and supported by strengthened supply chain and go-to-market capabilities.

With this, the company closed the 12-month Financial Year with reported sales of ₹1385 crores and PAT of ₹327 crores, up 16% and 30% respectively versus the comparable 12-month period last year (April 2024 - March 2025).

Considering that the company, effective last year, changed its Financial Year from a July 1 - June 30 period to a April 1 - March 31 period, the fiscal Year 2024-2025 of the Company covered a period of 9 months from July 1, 2024, to March 31, 2025. Therefore, the company performance has been indexed versus the comparable 12-months period in the last year (April 1, 2024, to March 31, 2025). The performance will not be comparable versus a 9-month past fiscal.

Milind Thatte, Managing Director, Procter & Gamble Health Limited, said, "We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers and healthcare professionals. These include superior innovations that are backed by science to help our consumers live healthier and more vibrant lives, and consumer communication initiatives, as well as strengthened go-to-market and supply chain capabilities.

We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization."

The Company's business continues to grow behind a strong suite of product innovations keeping the consumers at the centre. This includes the new Livogen Iron Gummies - a strawberry-flavoured, easy-toconsume, delightful format of iron supplementation and Neurobion Nerve Pain Relief Cream - a specialised topical solution designed to provide symptomatic relief from nerve-related pain, tingling and burning sensations in the hands and feet.

During the year, the Company continued to create a positive impact in the communities it serves through its Corporate Social Responsibility initiative - P&G Sehat. The initiative provides healthcare access and drives healthcare awareness in underserved communities across the country and has impacted over 15 lakh lives since its inception.

The Board of Directors have recommended a final dividend of ₹ 45/- per Equity Share for the Financial Year ended March 31, 2026, subject to the approval of Shareholders of the company at the ensuing 59thAnnual General Meeting. Considering the interim dividend of ₹160 per share paid on February 27, 2026, the total dividend payout for the fiscal will be ₹205 per share.

Shares of Procter & Gamble Health Limited was last trading in BSE at Rs. 5651.65 as compared to the previous close of Rs. 5721.40. The total number of shares traded during the day was 1024 in over 497 trades.

The stock hit an intraday high of Rs. 5754.20 and intraday low of 5597.55. The net turnover during the day was Rs. 5788062.00.

Source : Equity Bulls

Keywords

ProcterandGambleHealth INE199A01012 PGHL Pharmaceuticals Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate